{"entity":{"id":"kcnq5","kind":"target","name":"KCNQ5","aka":["potassium voltage-gated channel subfamily Q member 5","Potassium voltage-gated channel subfamily KQT member 5","Kv7.5"],"tldr":"KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","summary":"Pore-forming subunit of the voltage-gated potassium (Kv) channel broadly expressed in brain and involved in the regulation of neuronal excitability. Associates with KCNQ3/Kv7.3 pore-forming subunit to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons. Contributes, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current.\n\nOpen Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.74, genetic association 0.48, somatic mutation 0.23, clinical 0.76).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6299","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6299"},{"label":"UniProt Q9NR82","url":"https://www.uniprot.org/uniprotkb/Q9NR82/entry"},{"label":"NCBI Gene 56479","url":"https://www.ncbi.nlm.nih.gov/gene/56479"},{"label":"Ensembl ENSG00000185760","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185760"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"KCNQ5","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:6299","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6299","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9NR82","url":"https://www.uniprot.org/uniprotkb/Q9NR82/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000185760","url":"https://platform.opentargets.org/target/ENSG00000185760/associations","note":"association with cancer (MONDO_0004992) 0.57;  (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNQ5: RNA group enriched (bone marrow 4 nTPM, brain 13 nTPM, skeletal muscle 15 nTPM); high antibody staining in 1 normal tissue. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas KCNQ5 tissue","url":"https://www.proteinatlas.org/ENSG00000185760-KCNQ5/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000185760 associations","url":"https://platform.opentargets.org/target/ENSG00000185760/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:6299","ensembl":"ENSG00000185760","uniprot":"Q9NR82","entrez":"56479","firstDescribed":2000,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Lerche et al, J. Biol. Chem, 2000, \"Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/10787416/","biology":"Pore-forming subunit of the voltage-gated potassium (Kv) channel broadly expressed in brain and involved in the regulation of neuronal excitability. Associates with KCNQ3/Kv7.3 pore-forming subunit to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons. Contributes, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current. Also forms a functional channel with KCNQ1/Kv7.1 subunit that may contribute to vasoconstriction and hypertension. Channel may be selectively permeable in vitro to other cations besides potassium, in decreasing order of affinity K(+) = Rb(+) > Cs(+) > Na(+). Similar to the native M-channel, KCNQ3-KCNQ5 potassium channel is suppressed by activation of the muscarinic acetylcholine receptor CHRM1. Location: Cell membrane (UniProt). Locus 6q13 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/kcnq5/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}